THE GENECODE PLATFORM TECHNOLOGIES PATENTS
US Patent No.: US 8,901, 129 B2, Date of Patent Dec.2, 2014, European Patent No EP2509953, March 30, 2016
“METHODS OF FACILITATING NEURAL CELL SURVIVAL USING GDNF FAMILY LIGAND (GFL) MIMETICS OR RET SIGNALING PATHWAY ACTIVATORS”
The diseases, targeted by this GENECODE Patent protected inventions are listed in the background information of the Patent, section (0014):
 The disorders targeted by the present invention include Alzheimer´s disease, Huntington´s disease, amyotrophic lateral sclerosis, Rett syndrome, epilepsy, Parkinson´s disease, spinal cord injury, stroke, hypoxia, ischemia, brain injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation complications, motor neuron disease, multiple sclerosis, HIV dementia, peripheral nerve injury, hearing loss, depression, obesity, metabolic syndrome, pain, cancer, and other conditions involving degeneration or dysfunction of cells expressing GFRα/RET.
US Patent no., US 7,786, 292 B2, Date of Patent Aug. 31, 2010, European Patent No EP2013044, Aug. 29, 2012
“ANTISENSE AGENTS COMBINING STRONGLY BOUNDING BASE-MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE”
The diseases, targeted by this GENECODE Patent protected inventions are listed in the background information of the Patent:
The specific binding of antisense oligonucleotides to the DNA or RNA targets can inactivate the replication, transcription, or translation of nucleic acids, thereby providing mechanism for controlling diseases such as cancer and viral infection. The binding of antisense oligonucleotide to a target can be thus used to alter gene expression, in variety of circumstances, e.g. tom interfer with viral life cycles, or the growth of cancerous cells.